ReviewDeutsches Arzteblatt international2014
The diagnosis and graded therapy of atopic dermatitis.
Review in Deutsches Arzteblatt international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Topical Corticosteroid-Related Concerns and Phobic Behaviors in Saudi Arabia: A Cross-Sectional Investigation.Healthcare (Basel, Switzerland) · 2026Article
- Subclinical ocular surface changes in children with newly diagnosed allergy.Frontiers in pediatrics · 2025Article
- Differences in allergen-specific basophil activation and T cell proliferation in atopic dermatitis patients with comorbid allergic rhinoconjunctivitis treated with a monoclonal anti-IL-4Rα antibody or allergen-specific immunotherapy.Immunity, inflammation and disease · 2023Article
- Patient allocation method in major epidemics under the situation of hierarchical diagnosis and treatment.BMC medical informatics and decision making · 2022Article
- Atopic Dermatitis: Clinical Aspects and Unmet Needs.Biomedicines · 2022Review
- [Itchy skin changes after spending time outdoors].Dermatologie (Heidelberg, Germany) · 2022Article
- Case report: Optical coherence tomography for monitoring biologic therapy in psoriasis and atopic dermatitis.Frontiers in medicine · 2022Article
- Janus kinase inhibitors for the therapy of atopic dermatitis.Allergologie select · 2021Review
- Transcriptomes from German shepherd dogs reveal differences in immune activity between atopic dermatitis affected and control skin.Immunogenetics · 2020Article
- Sulforaphane has a therapeutic effect in an atopic dermatitis murine model and activates the Nrf2/HO‑1 axis.Molecular medicine reports · 2019Article
- Pancreatic Enzyme Supplementation in Patients with Atopic Dermatitis and Food Allergies: An Open-Label Pilot Study.Paediatric drugs · 2019Article
- Application of an agr-Specific Antivirulence Compound as Therapy for Staphylococcus aureus-Induced Inflammatory Skin Disease.The Journal of infectious diseases · 2018Article
- Keloid risk in patients with atopic dermatitis: a nationwide retrospective cohort study in Taiwan.BMJ open · 2018Article
- [Topical therapy for atopic eczema].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2018Review
- [Neurodermatitis : Atopy of the skin].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2017Review
- Systemic Treatment of Adult Atopic Dermatitis: A Review.Dermatology and therapy · 2017Review
- LILRA6 copy number variation correlates with susceptibility to atopic dermatitis.Immunogenetics · 2016Article
- S2k guideline on diagnosis and treatment of atopic dermatitis - short version.Allergo journal internationalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtopic dermatitis is the most common skin disease in children, with a prevalence of 10% to 15%, and is common in adults as well. Close coordination between primary care physicians and specialists is essential for the adequate treatment of chronically and severely affected patients.
methodThis article is a review of pertinent publications that were retrieved by a selective search in Pubmed, with additional consideration of the guidelines of the Association of Medical Scientific Societies in Germany (AWMF) and the European Dermatology Forum.
resultsTrigger factors such as skin irritants, allergens, microbial pathogens, and psychological factors can affect the condition of the skin differently in individual patients and should be individually assessed. The use of skin moisturising creams or emollients along with avoidance of specific and unspecific irritants is of great importance, as these patients have an impaired cutaneous barrier. Topical anti-inflammatory treatment with glucocorticoids or calcineurin inhibitors is a central part of the management of atopic dermatitis; in exceptional cases, severely affected patients are treated with systemic anti-inflammatory drugs. Interdisciplinary patient education has been found to be an effective tool in the complex management of this disease. Chronically and severely affected patients present special challenges for diagnosis and treatment.
conclusionRecent advances in the understanding of the molecular basis of cutaneous barrier disorders and of congenital and acquired immune disorders have led to new approaches to the treatment of atopic dermatitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.